MET-3 for Obesity

Phase 1

Waitlist Available

Led By Thomas Wolever, MD/PhD

Research Sponsored by NuBiyota

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline vs. week 7

Awards & highlights

No Placebo-Only Group

Summary

The purpose of this pilot study is to determine the effects of two human microbiome formulations (MET-3 and MET-5) on fasting serum TG concentration.

Eligible Conditions

Obesity

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline vs. week 7

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline vs. week 7

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline vs. week 7 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Fasting blood lipid levels

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: MET-5 2.5 g daily for 4 weeksExperimental Treatment1 Intervention

MET-5 is a new product composed of twenty-six strains of bacteria isolated from the stool of a different healthy donor than MET-3. Although it is expected to work in a similar fashion to MET-3, it contains some strains that are unique in comparison to the original MET-3 formulation and have been associated with leanness in the scientific literature. MET-5 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.

Group II: MET-3 2.5 g daily for 4 weeksExperimental Treatment1 Intervention

MET-3 is composed of twenty-two strains of bacteria and was designed to treat metabolic syndrome. The strains that were selected are based on strains that are known butyrate producers, associated with healthy subjects and improved gut barrier function. MET-3 is provided in capsule form and 5 capsules will be swallowed by each subject once daily for 4 weeks.

Do I qualify?Apply below to find out